NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough

Novavax (NVAX) is a biotechnology company headquartered in Gaithersburg, Maryland, focused on the discovery, development, and commercialization of vaccines that address serious infectious diseases. The company is best known for its protein-based Covid-19 vaccine, Nuvaxovid, and its proprietary Matrix-M adjuvant technology, which enhances immune response across a range of vaccine candidates. Novavax has increasingly shifted toward a partnership-driven business model, most notably through its expanded collaboration with Sanofi (SNY), which now leads commercial distribution of Nuvaxovid while Novavax focuses on supply, adjuvant sales, and pipeline development. This strategic pivot aims to lower fixed costs while positioning Novavax for a path toward sustainable long-term profitability.

NVAX Stock Climbs 

NVAX stock has been on a sharp upward trajectory recently, surging over 10% in a single session to close near $8.79, extending a broader rally in which shares have jumped more than 13% on strong days amid renewed sector-wide vaccine optimism. The stock is up roughly 34% year-to-date (YTD), though shares remain about 25% below their 52-week high near $11.97, set in February. NVAX is trading in the middle of its 52-week range and above its 200-day moving average, reflecting improving investor sentiment following the company's latest earnings beat and raised revenue guidance.

By comparison, the Nasdaq Composite ($NASX) has climbed roughly 13% YTD. Novavax's stock has notably outperformed the broader tech-heavy index this year, signaling renewed investor confidence in the company's leaner cost structure and improving path toward long-term financial stability.

Novavax Results Top Estimates 

Novavax reported second-quarter 2026 revenue of $56.7 million, down 76% year-over-year (YoY) but topping analyst estimates of roughly $55.9 million, as the comparison was skewed by $202 million in one-time milestone and amendment revenue recognized a year earlier. The adjusted loss per share came in at $0.32, beating the consensus estimate of a $0.38 loss by 16.6%, marking a notable earnings beat despite the steep year-over-year revenue decline.

Product sales rose 76% to $18.9 million, driven by strong Matrix-M adjuvant demand and supply sales to licensing partners, while Sanofi-related revenue totaled $36 million. Gross margin remained robust at nearly 75%, and combined GAAP R&D and SG&A expenses fell roughly 21% YoY as Novavax's cost-reduction program continued taking hold. The company ended the quarter with $743 million in cash and receivables, providing a solid liquidity cushion.

Management raised its full-year 2026 revenue guidance to a range of $235 million to $275 million, up from a prior midpoint of $250 million, citing strengthening momentum across its partnership pipeline. CEO John Jacobs said the company remains encouraged by its strategic progress, with executives reiterating confidence in Novavax's leaner operating model and its continued push toward sustainable profitability by 2028.

Biotech Stocks Spikes 

Novavax shares climbed sharply Wednesday as biotech stocks surged to their highest levels since the pandemic, fueled by a landmark trial success for a Moderna-Merck mRNA cancer therapy. While Novavax wasn't directly involved in the trial, it rode the sector-wide wave of optimism as investors rotated back into mRNA and vaccine-adjacent names following news that Intismeran Autogene, an individualized neoantigen therapy paired with Merck's Keytruda, hit its primary endpoint in the Phase 3 INTerpath-001 study for skin cancer. The breakthrough sent Moderna (MRNA) soaring more than 100% and Merck (MRK) up over 12%, lifting rival vaccine makers BioNTech (BNTX) and Novavax.

The rally pushed the SPDR S&P Biotech ETF (XBI) up more than 5% to its highest level since February 2021. For Novavax, the move adds fresh momentum on top of its recent earnings beat and raised 2026 revenue guidance, reinforcing renewed investor appetite across the broader vaccine and mRNA therapeutics space.

Is NVAX Stock a Buy After the Biotech Rally?

Novavax's sector-wide rally alongside Moderna's and Merck's mRNA cancer breakthrough highlights just how sensitive vaccine stocks remain to positive news across the space, even when the catalyst isn't company-specific. Wall Street's outlook stays cautiously constructive: NVAX holds a consensus "Moderate Buy" rating from analysts, with five "Strong Buy" calls tempered by a heavier mix of "Hold" and "Sell" ratings. Still, the average price target of $13.45 implies a substantial 50% upside from current levels, suggesting meaningful long-term potential for investors willing to navigate Novavax's ongoing volatility and execution risk.